Table I.
Primer and siRNA sequences.
| A, RT-qPCR primers | |
|---|---|
| Name | Sequence (5′-3′) |
| CASC2 (Forward) | GCACATTGGACGGTGTTTCC |
| CASC2 (Reverse) | CCCAGTCCTTCACAGGTCAC |
| EZH2 (Forward) | GGCTCCTCTAACCATGTTTACAACT |
| EZH2 (Reverse) | AGCGGTTTTGACACTCTG AACTAC |
| BCL2 (Forward) | TCT TCCAGGAACCTCTGTGATG |
| BCL2 (Reverse) | CAATGCCGCCATCGCTTACACC |
| GAPDH (Forward) | GCACCGTCAAGGCTGAGAAC |
| GAPDH (Reverse) | ATGGTGGTGAAGACGCCAGT |
| B, RIP-qPCR primers | |
| Name | Sequence (5′-3′) |
| CASC2 (Forward) | GCACATTGGACGGTGTTTCC |
| CASC2 (Reverse) | CCCAGTCCTTCACAGGTCAC |
| lncRNA control (Forward) | GGGTGTTTACGTAGACCAGAA |
| lncRNA control (Reverse) | CTTCCAAAAGCCTTCTGCCTTA |
| β-actin (Forward) | CTCGCTTCGGCAGCACATATAC |
| β-actin (Reverse) | AACGCTTCACGAATTTGCGTGT |
| C, ChIP-qPCR primers | |
| Name | Sequence (5′-3′) |
| BCL2-A (Forward) | GAGGAGCCATCCGCACATCA |
| BCL2-A (Reverse) | AGCTTAGACTGTAAGCTGGT |
| BCL2-B (Forward) | AGTCCCACAACAGCATAGGG |
| BCL2-B (Reverse) | TCCCTAGGTCAGGACCACCT |
| BCL2-C (Forward) | CTCCAGCTTGGGTGAAAGAG |
| BCL2-C (Reverse) | GGGCTTTTACACTTGGCTAG |
| GAPDH-D (Forward) | AGGGAAGCTGACAGGGATGGCG |
| GAPDH-D (Reverse) | ATCGAAGATGGACGAGTGGGTA |
| GAPDH-E (Forward) | CCCCGCTACTCCTCCTCCTAAG |
| GAPDH-E (Reverse) | TCCACGACCAGTTGTCCATTCC |
| D, siRNA | |
| Name | Sequence (5′-3′) |
| si-CASC2-1 | UGAAAAGAGCCGUGAGCUA |
| si-CASC2-2 | AAATAAAGATGGTGGAATG |
| si-CASC2-3 | CUGCAAGGCCGCAUGAUGA |
| si-EZH2 | AUCAGCUCGUCUGAACCUCUU |
| si-NC (GFP) | GGCUACGUCCAGGAGCGCACC |
siRNA, small interfering RNA; RT, reverse transcription; qPCR, quantitative PCR; CASC2, cancer susceptibility 2; EZH2, enhancer of zeste 2 polycomb repressive complex 2 subunit; RIP, RNA immunoprecipitation; ChiP, chromatin immunoprecipitation; NC, negative control.